NEW YORK (GenomeWeb) – Cantor Fitzgerald yesterday initiated coverage of Thermo Fisher Scientific with a rating of Overweight and a price target of $194 per share.

In a note to investors, Cantor analyst Bryan Brokmeier said that as the largest company in the highly-fragmented life science tools and diagnostics sector, Thermo Fisher has "significant opportunity for organic growth at the expense of weaker competitors," adding that the company is "well-positioned to benefit from positive secular trends, as well as capture share given its position in attractive end markets."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.

South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.

In Science this week: the synthetic genetic system hachimoji, and more.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.